Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Sep 21;15(1):210–219. doi: 10.1080/21645515.2018.1520581

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Author(s). Published with license by Taylor & Francis Group, LLC

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

PMC Copyright notice

Figure 7. — Effect of vaccine formulation on T cell phenotype.

T. cruzi-infected mice were treated with the indicated vaccine formulations, including saline solution, rTSA-1, MPLA, combinations of rTSA-1+ MPLA at doses of 5, 10 and 15 µg, and TSA-1 DNA (N = 4 to 7 mice per group). Splenocytes were harvested at 50 days post-infection, and stimulated in vitro with rTSA-1. Antigen-specific CD4+ (A and C) and CD8+ (B and D) T cells were analyzed for their production of IFNγ (A and B) and IL-4 (C and D) cytokines. Vaccine treatment resulted in significant differences in IFNγ-producing CD4+ (Kruskal-Wallis = 25.24, P < 0.001) and CD8 + T cells (Kruskal-Wallis = 25.96, P < 0.001), as well as in IL-4-producing CD4+ (Kruskal-Wallis = 13.51, P < 0.035) and CD8 + T cells (Kruskal-Wallis = 25.86, P < 0.001). * and ** indicate a significant difference with the saline control group (Dunn’s post-hoc test, P < 0.05 and P < 0.01, respectively).